Add BrightSurf on Google Email

A promising target for new RNA therapeutics now accessible

Researchers have identified the first inhibitors of the cancer-related RNA-modifier METTL16, which prevent its interaction with RNA. This breakthrough lays the foundation for novel RNA-targeting therapeutics and better investigation of METTL16's role in disease and health.

SourceMax Planck Institute of Molecular Physiology·JournalJACS Au·TypeExperimental study·DateApr 10, 2024